How Did AstraZeneca plc End Up Thrashing Rival GlaxoSmithKline plc?

AstraZeneca plc (LON: AZN) has handed out a real thrashing to pharmaceutical rival GlaxoSmithKline plc (LON: GSK) lately, but Harvey Jones suggests the tables could soon turn.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A couple of years ago, AstraZeneca (LSE: AZN) (NYSE: AZN.US) was the whipping boy of the pharmaceutical world. Its drugs pipeline was drying up, patents were expiring and sales were plunging. The share price had gone nowhere for ages. Brokers were giving it a beating, with a spate of downgrades. Even currency movements were against it. Astra was under the cosh.

GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), by contrast, was the much-admired head boy of FTSE pharmo. It had won applause for its strategy of cutting costs and offloading non-core holdings. Its drugs pipeline looked healthy and chief executive Sir Andrew Witty’s strategy of shifting from “white pills and western markets” towards consumer healthcare and emerging markets had been awarded top marks.

Tables Turned

Then look what happened. Glaxo’s share price grew a disappointing 12% over the past two years, trailing the FTSE 100’s return of nearly 18%. AstraZeneca, however, returned a startling 44%. No longer the whipping boy, AZN now holds the whip hand. So what went right (or wrong)?

AZNGolden boy Glaxo’s reputation has been tarnished by bribery scandals, in China, Iraq and Poland, with more apparently set to follow Jordan and Lebanon. For those who think these allegations don’t matter, pharmaceuticals and vaccines sales in China have since fallen 29%. 

Glaxo has also faced a string of patented expiries and late-stage failures, notably megablockbuster heart drug Darapaldib and cancer vaccine MAGE-A3. Maybe the signs were on the wall in February, when Warren Buffett sold off his remaining $17 million stake.

Big Pharmo, Big Deals

AstraZeneca has been shining by comparison. Its drugs pipeline is growing, with 104 ongoing projects, of which 90 are in the clinical phase of development. Revenues rose 3% to $6.4 billion in the first quarter. Its five designated growth areas (emerging markets, Japan, Brilinta and its diabetes and respiratory franchises) delivered an extra $1.2 billion of revenue in 2013.

All of which is very nice, but it’s takeover talk that has really got investor juices flowing. Astra’s shares soared 7% in a day on rumours that it is a target for US giant Pfizer. 

This added to the excitement gripping the sector, following the multi-billion dollar three-way link-up between Glaxo, Swiss drugmaker Novartis and US medicines group Eli Lilly, who plan to build a world-leading consumer healthcare business. Investors love a deal, and Glaxo also leapt 6% in a day. Big pharmo deal making is back, with a vengeance, it seems. 

AstraZeneca may have turned the tables on Glaxo, but it may struggle to hold its advantage for investors, especially if recent takeover speculation comes to nought. Glaxo’s three-part deal could really drive future shareholder value, especially if it allows the company to dispose of some of its established businesses. Astra may have thrashed its rival lately, but I reckon Glaxo is cracking the whip today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey doesn't own shares in any company mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »